Ommen S.R. Mital S. Burke M.A. et al.

AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy.

Circulation. 142https://doi.org/10.1161/cir.0000000000000937Elliott P.M. Anastasakis A. Borger M.A. et al.

Authors/Task Force m. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Eur Heart J. 35: 2733-2779Semsarian C. Ingles J. Maron M. et al.

New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy.

J Am Coll Cardiol. 65: 1249-1254Hindieh W. Weissler-Snir A. Hammer H. et al.

Discrepant Measurements of Maximal Left Ventricular Wall Thickness Between Cardiac Magnetic Resonance Imaging and Echocardiography in Patients With Hypertrophic Cardiomyopathy.

Circulation. 10Urbano-Moral J.A. Gonzalez-Gonzalez A.M. Maldonado G. et al.

Contrast-Enhanced Echocardiographic Measurement of Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy: Comparison with Standard Echocardiography and Cardiac Magnetic Resonance.

J Am Soc Echocardiogr. 33: 1106-1115Phelan D. Sperry B.W. Thavendiranathan P. et al.

Comparison of Ventricular Septal Measurements in Hypertrophic Cardiomyopathy Patients Who Underwent Surgical Myectomy Using Multimodality Imaging and Implications for Diagnosis and Management.

Am J Cardiol. 119: 1656-1662Neubauer S. Kolm P. Ho C. et al.

Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.

J Am Coll Cardiol. 74: 2333-2345Marstrand P. Han L. Day S.M. et al.

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction.

Circulation. 141: 1371-1383

Quantifying Diastolic Function in Hypertrophic Cardiomyopathy.

Circulation. 116: 2662-2665Nistri S. Olivotto I. Betocchi S. et al.

Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy).

Am J Cardiol. 98: 960-965Tsugu T. Nagatomo Y. Dulgheru R. et al.

Layer-specific longitudinal strain predicts left ventricular maximum wall thickness in patients with hypertrophic cardiomyopathy.

Echocardiography. 38: 1149-1156Li Y. Liu J. Cao Y. et al.

Predictive values of multiple non-invasive markers for myocardial fibrosis in hypertrophic cardiomyopathy patients with preserved ejection fraction.

Sci Rep. 11: 4297Tower-Rader A. Mohananey D. To A. et al.

Prognostic Value of Global Longitudinal Strain in Hypertrophic Cardiomyopathy.

J Am Coll Cardiol Img. 12: 1930-1942Hiemstra Y.L. Debonnaire P. Bootsma M. et al.

Global Longitudinal Strain and Left Atrial Volume Index Provide Incremental Prognostic Value in Patients With Hypertrophic Cardiomyopathy.

Circulation. 10Vigneault D.M. Yang E. Jensen P.J. et al.

Left Ventricular Strain Is Abnormal in Preclinical and Overt Hypertrophic Cardiomyopathy: Cardiac MR Feature Tracking.

Radiology. 290: 640-648Negri F. Muser D. Driussi M. et al.

Prognostic role of global longitudinal strain by feature tracking in patients with hypertrophic cardiomyopathy: The STRAIN-HCM study.

Int J Cardiol. 345: 61-67Moravsky G. Ofek E. Rakowski H. et al.

Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.

JACC. 6: 587-596Weng Z. Yao J. Chan R.H. et al.

Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.

JACC. 9: 1392-1402Ismail T.F. Jabbour A. Gulati A. et al.

Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy.

Heart. 100: 1851-1858Chan R.H. Maron B.J. Olivotto I. et al.

Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy.

Circulation. 130: 484-495Rubinshtein R. Glockner J.F. Ommen S.R. et al.

Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy.

Circulation. 3: 51-58Ho C.Y. Abbasi S.A. Neilan T.G. et al.

T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy.

Circulation. 6: 415-422Rao S. Tseng S.Y. Pednekar A. et al.

Myocardial Parametric Mapping by Cardiac Magnetic Resonance Imaging in Pediatric Cardiology and Congenital Heart Disease.

Circulation. 15https://doi.org/10.1161/circimaging.120.012242Menghoum N. Vos J.L. Pouleur A.C. et al.

How to evaluate cardiomyopathies by cardiovascular magnetic resonance parametric mapping and late gadolinium enhancement.

Eur Heart J Card Imag. 23: 587-589Geske J.B. Sorajja P. Nishimura R.A. et al.

Evaluation of Left Ventricular Filling Pressures by Doppler Echocardiography in Patients with Hypertrophic Cardiomyopathy.

Circulation. 116: 2702-2708Maron B.J. Haas T.S. Maron M.S. et al.

Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance.

Am J Cardiol. 113: 1394-1400Yang H. Woo A. Monakier D. et al.

Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity.

J Am Soc Echocardiogr. 18: 1074-1082Maron M.S. Olivotto I. Harrigan C. et al.

Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy.

Circulation. 124: 40-47

The Mitral Valve in Hypertrophic Cardiomyopathy.

Circulation. 124: 9-12Maron M.S. Olivotto I. Harrigan C. et al.

Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy.

Circulation. 124: 40-47Ibrahim M. Rao C. Ashrafian H. et al.

Modern management of systolic anterior motion of the mitral valve.

Eur J Cardio Thorac Surg. 41: 1260-1270Shah J.S. Esteban M.T. Thaman R. et al.

Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy.

Heart. 94: 1288-1294Maron M.S. Olivotto I. Zenovich A.G. et al.

Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction.

Circulation. 114: 2232-2239Maron M.S. Olivotto I. Betocchi S. et al.

Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy.

N Engl J Med. 348: 295-303Joshi S. Patel U.K. Yao S.S. et al.

Standing and Exercise Doppler Echocardiography in Obstructive Hypertrophic Cardiomyopathy: The Range of Gradients with Upright Activity.

J Am Soc Echocardiogr. 24: 75-82Marwick T.H. Nakatani S. Haluska B. et al.

Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy.

Am J Cardiol. 75: 805-809Feiner E. Arabadjian M. Winson G. et al.

Post-Prandial Upright Exercise Echocardiography in Hypertrophic Cardiomyopathy.

J Am Coll Cardiol. 61: 2487-2488Geske J. Sorajja P. Ommen S. et al.

Variability of Left Ventricular Outflow Tract Gradient During Cardiac Catheterization in Patients With Hypertrophic Cardiomyopathy.

J Am Coll Cardiol Intv. 4: 704-709Ayoub C. Geske J.B. Larsen C.M. et al.

Comparison of Valsalva Maneuver, Amyl Nitrite, and Exercise Echocardiography to Demonstrate Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy.

Am J Cardiol. 120: 2265-2271Jensen M.K. Havndrup O. Pecini R. et al.

Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy.

Eur J Echocardiogr. 11: 763-769Reant P. Dufour M. Peyrou J. et al.

Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study.

Eur J Cardio Thorac Surg. 19: 31-38Binder J. Attenhofer Jost C.H. Klarich K.W. et al.

Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching.

J Am Soc Echocardiogr. 24: 775-781Cardim N. Galderisi M. Edvardsen T. et al.

Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association.

Eur J Cardio Thorac Surg. 16: 280Maron M.S. Finley J.J. Bos J.M. et al.

Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy.

Circulation. 118: 1541-1549To A. Dhillon A. Desai M. et al.

Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy.

J Am Coll Cardiol Img. 4: 1123-1137Vasquez N. Ostrander B.T. Lu D.Y. et al.

Low Left Atrial Strain Is Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy Patients.

J Am Soc Echocardiogr. 32: 593-603Tayal B. Malahfji M. Buergler J.M. et al.

Hemodynamic determinants of left atrial strain in patients with hypertrophic cardiomyopathy: A combined echocardiography and CMR study.

PLoS One. 16: e0245934Sivalokanathan S. Zghaib T. Greenland G.V. et al.

Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging.

JACC. 5: 364-375Papavassiliu T. Germans T. Flüchter S. et al.

CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation.

J Cardiovasc Magn Reson. 11: 34Kramer C. DiMarco J. Kolm P. et al.

Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR.

J Am Coll Cardiol EP. 7: 1376-1386

Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta-Adrenergic Blockade.

Circulation. 35: 847-851Stenson R.E. Flamm Jr., M.D. Harrison D.C. et al.

Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy.

Am J Cardiol. 31: 763-773Nistri S. Olivotto I. Maron M.S. et al.

β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy.

Am J Cardiol. 110: 715-719Gilligan D. Chan W. Joshi J. et al.

A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy.

J Am Coll Cardiol. 21: 1672-1679Wilmshurst P.T. Thompson D.S. Juul S.M. et al.

Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy.

Heart. 56: 544-553Rosing D.R. Kent K.M. Borer J.S. et al.

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects.

Circulation. 60: 1201-1207Ammirati E. Contri R. Coppini R. et al.

Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.

Eur J Heart Fail. 18: 1106-1118Sherrid M. Barac I. McKenna W. et al.

Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.

J Am Coll Cardiol. 45: 1251-1258Olivotto I. Oreziak A. Barriales-Villa R. et al.

EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 396 (): 759-769Saberi S. Cardim N. Yamani M. et al.

Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy.

Circulation. 143: 606-608Hegde S. Lester S. Solomon S. et al.

Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.

J Am Coll Cardiol. 78: 2518-2532Sorajja P. Valeti U. Nishimura R.A. et al.

Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy.

Circulation. 118: 131-139Ommen S. Maron B. Olivotto I. et al.

Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy.

J Am Coll Cardiol. 46: 470-476Liebregts M. Vriesendorp P. Mahmoodi B. et al.

A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy.

J Am Coll Cardiol HF. 3: 896-905Grigg L.E. Wigle E.D. Williams W.G. et al.

Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making.

J Am Coll Cardiol. 20: 42-52Marwick T.H. Stewart W.J. Lever H.M. et al.

Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy.

J Am Coll Cardiol. 20: 1066-1072Faber L. Ziemssen P. Seggewiss H.

Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring.

J Am Soc Echocardiogr. 13: 1074-1079Faber L. Seggewiss H. Ziemssen P. et al.

Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area.

Cathet Cardiovasc Intervent. 47: 462-466Tang B. Song Y. Cheng S. et al.

In-Hospital Postoperative Atrial Fibrillation Indicates a Poorer Clinical Outcome after Myectomy for Obstructive Hypertrophic Cardiomyopathy.

Ann Thorac Cardiovasc Surg. 26: 22-29Kwon D.H. Smedira N.G. Rodriguez E.R. et al.

Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia.

J Am Coll Cardiol. 54: 242-249